In this paper, we reported our own experience with diphenylhydantoin (DPH). On the basis of this experience, as well as the wide literature search that we conducted, we personally believe that DPH is superior to the most widely used medication (Diazoxide) in suppressing insulin secretion, Refs. [1], [2]. Our article is published in the category of a Case Report, based upon personal experience, and is not intended to generate recommendations or guidelines. We suggest considering DPH as a temporary therapeutic measure in the preoperative period of patients with insulinoma, as well as an alternative measure for inoperable insulinomas, something that has already been successfully done by others [3], [4].
References
[1]. [1]Levin SR, Grodsky GM, Hagura R, et al.Comparison of the inhibitory effects of diphenylhydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas. Diabetes. 1972;21:856–862. MEDLINE
[2]. [2]Kizer JS, Vargas-Cordon M, Brendel K, et al.The in vitro inhibition of insulin secretion by diphenylhydantoin. J Clin Invest. 1970;49(10):1942–1948. MEDLINE |
CrossRef
[3]. [3]Cohen MS, Bower RH, Fidler SM, et al.Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet. 1973;301(7793):40–41.
CrossRef
[4]. [4]Imanaka S, Matsuda S, Ito K, et al.Medical treatment for inoperable Insulinoma: clinical usefulness of diphenylhydantoin and diltiazem. Jpn J Clin Oncol. 1986;16:65–71. MEDLINE
The Methodist Hospital, Texas, United States. Tel.: +1 281 736 7848
FULL TEXT